HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Noninfiltrating Intraductal Carcinoma (DCIS)

A noninvasive (noninfiltrating) carcinoma of the breast characterized by a proliferation of malignant epithelial cells confined to the mammary ducts or lobules, without light-microscopy evidence of invasion through the basement membrane into the surrounding stroma.
Also Known As:
DCIS; Ductal Carcinoma In Situ; Intraductal Carcinoma; Carcinoma, Intraductal; Carcinoma, Intraductal, Noninfiltrating; Atypical Ductal Hyperplasia; Intraductal Carcinoma, Noninfiltrating; Atypical Ductal Hyperplasias; Carcinoma, Noninfiltrating Intraductal; Carcinomas, Intraductal; Carcinomas, Noninfiltrating Intraductal; Ductal Hyperplasia, Atypical; Ductal Hyperplasias, Atypical; Hyperplasia, Atypical Ductal; Hyperplasias, Atypical Ductal; Intraductal Carcinomas; Intraductal Carcinomas, Noninfiltrating; Noninfiltrating Intraductal Carcinomas
Networked: 3871 relevant articles (117 outcomes, 674 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Noninfiltrating Intraductal Carcinoma (DCIS)
2. Breast Neoplasms (Breast Cancer)
3. Neoplasms (Cancer)
4. Carcinoma (Carcinomatosis)
5. Hyperplasia

Experts

1. Morrow, Monica: 43 articles (04/2022 - 09/2002)
2. Hwang, E Shelley: 37 articles (07/2022 - 01/2004)
3. Kuerer, Henry M: 35 articles (01/2022 - 10/2003)
4. Schnitt, Stuart J: 29 articles (11/2022 - 09/2002)
5. Van Zee, Kimberly J: 27 articles (04/2021 - 04/2003)
6. Rakha, Emad A: 26 articles (05/2022 - 08/2012)
7. Rakovitch, Eileen: 26 articles (02/2022 - 09/2005)
8. Wesseling, Jelle: 23 articles (07/2022 - 06/2007)
9. Green, Andrew R: 23 articles (05/2022 - 09/2012)
10. Hunt, Kelly K: 21 articles (01/2019 - 11/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Noninfiltrating Intraductal Carcinoma:
1. TamoxifenFDA LinkGeneric
2. Hormones (Hormone)IBA
3. Anastrozole (Arimidex)FDA LinkGeneric
4. Estrogen ReceptorsIBA
5. Phenobarbital (Luminal)FDA Link
07/01/2019 - "Furthermore, coexistence of DCIS component in IDC significantly improved DFS in HER2 positive (94.8% vs 78.5%, P = 0.003), but had no association in luminal and triple negative subtypes. "
01/01/2018 - "The results of this study suggest that the ever use of LO + ON + OTC does not influence the overall incidence of benign breast condition or malignant disease compared to other COCs; however, patients that have used OTC had an association with a diagnosis of benign or luminal A pathologies whereas ON was associated with a diagnosis of benign and DCIS; LO showed no association with any diagnosis-benign or malignant. "
04/01/2012 - "In total, 180 cases of DCIS were included in the study (luminal A, n=113; luminal B, n=25; HER2neu type, n=29; triple negative, n=13). "
05/01/2011 - "We define those cases as DCIS with invasion component (DCIS-I), and attempt to study the differences of clinicopathological features and immunohistochemical-based subtypes among DCIS, DCIS-Mi, and DCIS-I. In this retrospective study, 550 consecutive DCIS patients were recruited, 271 (49.3%) cases were diagnosed as pure-DCIS, 67 as DCIS-Mi, and 212 as DCIS-I. They were categorized into four groups: luminal-A (ER+ and/or PR+, HER2-), luminal-B (ER+ and/or PR+, HER2+), ERBB2+ (ER-, PR-, HER2+), and basal-like (ER-, PR-, HER2-). "
10/18/2022 - "Conversely, NRAS overexpression in the luminal DCIS SUM225 cells induced a basal-like gene expression pattern, as well as an epithelial-to-mesenchymal transition signature. "
6. Aromatase InhibitorsIBA
7. Proteins (Proteins, Gene)FDA Link
8. Trastuzumab (Herceptin)FDA Link
9. Docetaxel (Taxotere)FDA Link
10. Cadherins (E-Cadherin)IBA

Therapies and Procedures

1. Therapeutics
2. Radiotherapy
3. Segmental Mastectomy (Lumpectomy)
4. Mastectomy (Mammectomy)
5. Drug Therapy (Chemotherapy)